Caribou Biosciences (CRBU) Other Non-Current Assets (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Other Non-Current Assets of $2.1 million for Q1 2026, down 57.62% year-over-year from $5.0 million in Q1 2025, and down 2.86% quarter-over-quarter from $2.2 million in Q4 2025.
Caribou Biosciences (CRBU) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Other Non-Current Assets for 7 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 57.62% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (down 57.62% YoY), while the FY2025 annual figure was $2.2 million, down 60.15% from the prior year.
- Other Non-Current Assets retreated to $2.1 million in Q1 2026 per CRBU's latest filing, from $2.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.5 million in Q4 2024 and bottomed at $1.3 million in Q2 2022.
- Historically, Other Non-Current Assets has averaged $2.5 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 61.63% — and 2024, when it jumped 248.11%.
- Caribou Biosciences' Other Non-Current Assets stood at $1.5 million in 2022, then advanced by 3.12% to $1.6 million in 2023, then surged by 248.11% to $5.5 million in 2024, then tumbled by 60.15% to $2.2 million in 2025, then fell by 2.86% to $2.1 million in 2026.
- Business Quant data shows CRBU's Other Non-Current Assets at $2.1 million in Q1 2026, $2.2 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 2.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.14 Mn |
| Mar 31, 2026 | 2.14 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 3.78 Mn |
| Jun 30, 2025 | 3.63 Mn |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 5.52 Mn |
| Sep 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.54 Mn |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 1.46 Mn |
| Dec 31, 2021 | 975,000.00 |
| Sep 30, 2021 | 810,000.00 |